
Unity Biotechnology said Monday that its experimental treatment for osteoarthritis failed to improve knee pain compared to a placebo in a mid-stage clinical trial.
The outcome is likely to raise new doubts about the biotech’s ability to develop drugs to reverse the symptoms and diseases associated with aging.